Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pharmacokinetics of paroxetine in patients with cirrhosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Improving the management of the paracetamol poisoned patient

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20-30 mg paroxetine daily was adjusted to the reduction in liver function, as assessed by the galactose elimination capacity. Accordingly, all but two of the cirrhotic patients received 20 mg, while all six control subjects received 30 mg. Dose-corrected, trough drug concentration at steady state (CSSmin) and dose-corrected AUC24h were significantly higher in the patients with liver diseases than in the control subjects [3.4 vs 1.5 ng.ml-1 per mg paroxetine and 89 vs 43 h (ng).ml-1 per mg paroxetine]. The elimination t1/2 was prolonged [83 vs 36 h], but the difference was not statistically significant, and the cirrhotic patients were still able to clear almost all the paroxetine by metabolism. All but two patients with cirrhosis experienced nausea during the first two or three days after the first dose, while none of the controls had this symptom. The study showed slower elimination of paroxetine and consequently higher plasma levels in patients with cirrhosis, suggesting that in the latter the dose of paroxetine should be in the lower end of the therapeutic range.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Pharmacology
Vol/bind41
Udgave nummer4
Sider (fra-til)351-4
Antal sider4
ISSN0031-6970
DOI
StatusUdgivet - 1991

ID: 49583854